ORYZON Receives the US FDA’s IND Clearance to Initiate a Collaborative P-II Basket Study of Iadademstat for Neuroendocrine Carcinomas
Shots:
- The US FDA has cleared an IND application to initiate the collaborative P-II open-label basket study of iadademstat in patients with r/r high-grade NEC. The study will be conducted under a joint clinical research agreement b/w Oryzon and the Fox Chase Cancer Center
- Oryzon will be responsible for providing funding, drug, and technical expertise while Iadademstat is currently under clinical development for hematologic cancers and solid tumors. In an ongoing & P-IIa (ALICE) trial, the therapy showed encouraging safety & efficacy data in combination with azacytidine for AML
- The company initiate the P-Ib trial of iadademstat for FLT3 mutant r/r AML in combination with gilteritinib & is planning to start the new P-Ib/II (STELLAR) trial for SCLC in combination with immune checkpoint inhibitors
Ref: Globenewswire | Image: ORYZON
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
